Study: Early statin use carries ‘lifetime effect’ |

Study: Early statin use carries ‘lifetime effect’

The Associated Press

CHICAGO — Taking a cholesterol-lowering drug for five years in middle age can lower heart and death risks for decades afterward, and the benefits seem to grow over time, a landmark study finds. Doctors say it’s the first evidence that early use of a statin can have a legacy effect, perhaps changing someone’s odds of disease for good.

“It might be a lifetime effect,” said one study leader, Dr. Chris Packard of the University of Glasgow in Scotland.

Not only did original benefits of statins continue into late life, but researchers were surprised to see new ones become evident, he said.

The results are from the West of Scotland Coronary Prevention Trial, the first study ever to show that statins could prevent heart problems in people who had not yet developed clogged arteries but had high LDL, the bad type of cholesterol.

The watershed trial led to these drugs — sold as Lipitor, Crestor, Zocor and now in generic form — becoming a mainstay of treatment and one of the most prescribed medicines around the world.

The long-term results were discussed at an American Heart Association conference that ended Wednesday in Chicago.

The study, which started in 1989, involved about 6,600 Scottish men, ages 45 to 64, with high LDL — around 190, on average. Half were given the statin Pravachol and the rest, dummy pills. Five years later, there were 35 percent fewer heart-related deaths and fewer heart attacks in the statin group.

Once the study ended, the men went back to their regular doctors, and about one-third of both groups kept or started taking a statin. This means any differences seen years later probably are due to whether the patients took statins during the five-year study, Packard explained.

Scotland has national health care and good electronic medical records, so researchers were able to document what happened to more than 90 percent of the men.

Twenty years after the study began, the risk of heart-related deaths was 27 percent lower among the men who took Pravachol for those first five years rather than dummy pills.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.